To summarize, despite the remarkable advances that have been achieved within passive and active immunotherapies, so far the HER2 targeted therapies in combination with other treatments give some promising results for BC patients, whilst, a multitude of patients with TNBC still await to receive a cure for this deadly disease. This evidence concerns the gene ERBB2 and breast cancer.